Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 2c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $54.3 million versus the consensus estimate of $51.45 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2024 revenue of $198-202 million, versus the consensus of $193.4 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Belden prices $1.85 billion term loan to fund RUCKUS acquisition
• SpaceX: New Street Research sees 22% upside from proposed IPO price